FPFT-2216, a novel anti-lymphoma compound, induces simultaneous degradation of IKZF1/3 and CK1α to activate p53 and inhibit NF-κB signaling
Article in Cancer Research Communications (February 2024)
The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.
Article in Cancer Research Communications (February 2024)
Article in Nature Communications (August 2023)
Article in The Annual Review of Pharmacology and Toxicology (August 2023)